Telix Pharma Concludes Acquisition of Antibody Engineering Firm ImaginAb

Telix Pharmaceuticals Limited, a biopharmaceutical firm dedicated to the advancement and marketing of therapeutic and diagnostic radiopharmaceuticals alongside related medical technologies, declared that it has finalized the acquisition from the antibody engineering firm ImaginAb, Inc. (ImaginAb).

The acquisition encompasses a pipeline of advanced therapeutic candidates, a unique novel biologics technology platform, and a research facility for protein engineering and discovery to boost current innovation capabilities.

This agreement provides a series of drug candidates targeting proven cancer markers such as DLL32 and integrin avß63, along with a selection of additional compounds aimed at innovative targets in the early stages of discovery. The company is confident that these next-generation drug candidates align synergistically with Telix's therapeutic pipeline, facilitating expansion into future treatment areas with unmet clinical demands.

The technology platform and intellectual property employ small, designed antibody formats that facilitate precise targeting of cancer with radiation, showing rapid tumor absorption and blood elimination. This technology could be very effective for imaging and treating tumors using a wide variety of radioisotopes, especially alpha emitters. The combination of ImaginAb's capabilities with Telix’s current investments in new target development, conjugation, and isotope processing has produced a platform that may swiftly generate a new range of “next generation” theranostic radiopharmaceuticals.